Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has reported that its Taxotere drug has been accepted for filing and assigned priority review status by the FDA for the treatment of head and neck cancer.
Subscribe to our email newsletter
The drug will treat patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery.
The French drug maker, the third largest in the world, explained that the FDA grants priority review to products that, if approved, would be a significant improvement compared to marketed products, including non-drug products in the treatment, diagnosis or prevention of a disease.
To date, Taxotere has received a total of seven indications in the US.